Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

CSCS

SURGERY

CARDIAC SURGERY STATE OF THE ART LECTURES: EDITORS ROUNDTABLE

262 - Q & A -CARDIAC SURGERY STATE OF THE ART LECTURES EDITORS ROUNDTABLE

Friday, October 25, 2024
4:30 PM – 5:30 PM PT
Room: 116-117
This session encompasses a discussion of publication strategies of leading cardiovascular medical journals and leadership in cardiac surgery

Learning Objectives:

At the end of this session participants will be able to:
  • Appreciating vision and mission of leading cardiovascular medical journals
  • Understanding what is required to be an effective leader as a cardiac surgeon
Disclosure(s):
Maral Ouzounian, MD PhD: Antonio & Helga DeGasperis Chair in Clinical Trials and Outcomes Research: Funded Chair (Ongoing); Munk Chair in Advanced Therapeutics: Chair (Ongoing)
Subodh Verma, MD PhD FRCSC FAHA FCCS FCAHS: Amarin: Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Astrazeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Canadian Medical and Surgical Knowledge Translation Research Group: Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Humber River Health: Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); PhaseBio: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); S & L Solutions Event Management Inc: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Sun Pharma: Speaker/Honoraria (Ongoing)
Ansar Hassan, MD: No financial relationships to disclose